Psychotic disorders involve abnormalities in one or more of the five domains: delusions, hallucinations, disorganized thinking, grossly disorganized or abnormal motor behavior, and negative symptoms. Schizophrenia is the prototypical psychotic disorder, a severe and chronic condition that affects approximately 0.5–1% of the population worldwide.

Brain scan — Psychotic disorders involve disturbances in thought, perception, and reality testing. Schizophrenia affects approximately 24 million people worldwide. Source: Unsplash.

Psychotic Symptoms

Positive symptoms — an excess or distortion of normal functions. Delusions are fixed false beliefs held with strong conviction despite contradictory evidence. Common themes: persecutory (believing one is being threatened or conspired against), referential (believing random events or comments are directed at oneself), grandiose (believing one has special powers or identity), somatic (believing one has a physical abnormality or disease), and nihilistic (believing that a catastrophe has occurred or that the self or world does not exist). Hallucinations are perception-like experiences without an external stimulus, most commonly auditory (voices commenting, conversing, or commanding), but also visual, tactile, olfactory, or gustatory. Disorganized thinking manifests as loose associations, tangentiality, derailment, and incoherence. Grossly disorganized behavior includes unpredictable agitation, inappropriate affect, catatonia, and bizarre appearance.

Negative symptoms — a diminution or loss of normal functions. The five A’s: alogia (poverty of speech), affective flattening (reduced emotional expression), anhedonia (loss of pleasure), asociality (reduced social drive), and avolition (reduced goal-directed activity). Negative symptoms are more persistent and disabling than positive symptoms and respond poorly to antipsychotic medication.

Cognitive symptoms. Impairments in attention, working memory, executive function, processing speed, and social cognition. Cognitive deficits are present before psychosis onset and predict functional outcome more strongly than positive symptom severity.

Schizophrenia

Psychosis abstract — Schizophrenia is a chronic psychotic disorder involving delusions, hallucinations, disorganized thinking, and negative symptoms. Source: Unsplash.

DSM-5 Criteria

Two or more of the following, each present for a significant portion of time during a one-month period (or less if successfully treated), with at least one being delusions, hallucinations, or disorganized speech: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. Continuous signs of disturbance must persist for at least six months, including at least one month of active-phase symptoms. Social or occupational dysfunction in work, interpersonal relations, or self-care must be present. Schizoaffective disorder and bipolar or depressive disorder with psychotic features must be ruled out.

Course and Prognosis

The prodromal phase — social withdrawal, declining functioning, cognitive difficulties, and subthreshold psychotic-like experiences — precedes the first psychotic episode by months to years. The first episode typically occurs in late adolescence or early adulthood (late teens to early 20s for men, mid-20s to early 30s for women). After the first episode, the course is variable — approximately 20% have a single episode with full recovery, 60% have relapsing-remitting course with residual symptoms, and 20% have persistent, severe symptoms. Poor prognostic factors: earlier onset, male sex, longer duration of untreated psychosis, prominent negative symptoms, cognitive impairment, poor premorbid functioning, and family history.

Neurobiology

The dopamine hypothesis has been the dominant neurochemical model. Hyperactivity of mesolimbic dopamine pathways contributes to positive symptoms, while hypoactivity of mesocortical dopamine pathways contributes to negative and cognitive symptoms. All effective antipsychotics block D2 dopamine receptors. The glutamate hypothesis proposes that NMDA receptor hypofunction on GABAergic interneurons leads to disinhibition of glutamate release, contributing to all symptom domains. This is supported by the observation that NMDA antagonists (PCP, ketamine) produce a schizophrenia-like syndrome in healthy individuals. Neuroimaging reveals enlarged lateral ventricles, reduced gray matter volume (particularly in prefrontal and temporal cortex), and reduced hippocampal volume. Dysconnectivity — altered functional connectivity between brain networks — is a core feature, particularly impaired connectivity between prefrontal and temporal regions.

⚠ Clinical Correlation

First-generation (typical) antipsychotics: haloperidol, chlorpromazine, fluphenazine. They primarily block D2 receptors and are effective for positive symptoms but cause extrapyramidal side effects (acute dystonia, parkinsonism, akathisia, tardive dyskinesia). Second-generation (atypical) antipsychotics: clozapine, risperidone, olanzapine, quetiapine, aripiprazole, paliperidone, lurasidone, cariprazine. They block D2 and 5-HT2A receptors, causing fewer extrapyramidal effects but significant metabolic side effects (weight gain, diabetes, dyslipidemia). Clozapine is uniquely effective for treatment-resistant schizophrenia but requires regular blood monitoring due to the risk of agranulocytosis. Long-acting injectable antipsychotics improve adherence. Antipsychotic selection is based on side effect profile, patient preference, and prior response.

Other Psychotic Disorders

Schizoaffective disorder. Meets criteria for schizophrenia and a major mood episode (depressive or manic) concurrently for at least two weeks, with psychotic symptoms present for at least two weeks without a major mood episode. Treatment combines antipsychotics and mood stabilizers.

Delusional disorder. One or more delusions persisting for at least one month without meeting full criteria for schizophrenia. Functioning is less impaired than in schizophrenia, and behavior is not obviously bizarre. Common subtypes: persecutory, jealous, grandiose, erotomanic, and somatic. Treatment is challenging — antipsychotics have modest efficacy, and therapeutic alliance is key.

Brief psychotic disorder. Sudden onset of one or more psychotic symptoms lasting at least one day but less than one month, often with a stressor. Typically resolves fully.

Schizophreniform disorder. Symptoms identical to schizophrenia but lasting one to six months. Approximately two-thirds convert to schizophrenia.

Substance-induced psychotic disorder. Psychosis due to intoxication or withdrawal from substances (stimulants, cannabis, hallucinogens, alcohol). Typically resolves with abstinence.

Treatment Beyond Medication

Cognitive behavioral therapy for psychosis (CBTp). Helps patients develop alternative explanations for psychotic experiences, reduce distress, and improve coping. CBTp reduces positive symptoms and relapse rates.

Cognitive remediation. Computer-based training to improve attention, memory, and executive function. Produces modest improvements in cognition and everyday functioning.

Social skills training. Teaches communication, assertiveness, and interpersonal skills to improve social functioning.

Supported employment and education. Individual placement and support (IPS) helps patients obtain and maintain competitive employment. Supported education assists with completion of educational goals.

Assertive community treatment (ACT). Multidisciplinary team providing intensive, community-based treatment for high-need patients.

★ Key Concept

The duration of untreated psychosis (DUP) — the time between first psychotic symptoms and initiation of adequate treatment — is consistently associated with poorer outcomes. Extended DUP predicts lower rates of remission, greater symptom severity, and worse social and occupational functioning. Early intervention services (EIS) provide rapid access to comprehensive, phase-specific treatment for first-episode psychosis. Core components: low-dose antipsychotic medication, CBTp, family education and support, vocational support, and case management. Coordinated specialty care (CSC) programs — such as NAVIGATE and RAISE — have demonstrated superior outcomes compared to standard care. Reducing DUP through public education and streamlined referral pathways is a public health priority.

Summary

Schizophrenia is a chronic, severe psychotic disorder with positive, negative, and cognitive symptom domains. Antipsychotic medications effectively treat positive symptoms but have limited efficacy for negative and cognitive symptoms. Evidence-based psychosocial treatments — CBTp, cognitive remediation, social skills training, and supported employment — complement pharmacotherapy. Early intervention in first-episode psychosis improves outcomes. Despite the chronic nature of the illness, many individuals with schizophrenia achieve meaningful recovery with comprehensive, continuous treatment.